Augusta Resource Corporation (the Company) is base metals Company engaged in the acquisition, exploration and development of natural mineral resource properties. The Company’s goals is to build and operate a world-class Rosemont mine while developing a vigorous portfolio of assets in North America which focuses on organic growth in the earliest stage of acquisition. The Company’s experience and the strength of its management team, coupled with high class infrastructure project sets it to become one of the leading copper development and mining company.

At present, he Company’s only material property is the Rosemont copper property located in Pima County, Arizona which is primarily a copper mining project with appreciable amounts of molybdenum and silver by-products. It hosts a large copper/molybdenum reserve of 5.2 billion pounds of copper and 161 million pounds of molybdenum.

The property consists of:

•  132 patented lode claims consisting of about 797 hectares
• contiguous package of 949 unpatented lode mining claims consisting of (4,860 hectares which surround the core of patented claims.
• 10 blocks of fee land associated with the property, consisting of a number of individual parcels that enclose an additional 911 acres (369 hectares).

The project is almost at the last stages of acquiring permit and the record of decision is expected to be released on the 3^rd quarter of 2012 while the construction is expected to begin in the 3^rd or 4^th quarter of the same year. Once Rosemont is in operation, produce 221 million pounds of copper per year, which could account for as much as 10% of US copper output thereby making it to be one of the largest copper mines in the United States.

Augusta Resource Corp. (USA) (NYSEAMEX: AZC) 52 week: 2.10 – 5.55   Mkt cap: 369.14M   Shares: 144.20M

Incorporated in 1992, AudioCodes Ltd. (the Company) is engaged in designing, developing and selling of products for voice and data over packet networks. The products of the Company provide the media a gateway element in the network and voice over Internet Protocol (VoIP) which in turn includes Internet Protocol Phones and VoIP mobile clients. The Company categorizes its products into two main business lines namely: network and technology which facilitate the transmission of voice, data and fax over packet networks. Network products consist of the following:

• customer premises equipment (CPE)
• gateways for the enterprise and service provider (or carrier) markets
• carrier-grade-oriented low- and mid-density media gateways for service providers.

Networking products of the Company would include the following:

• analog media gateways for toll bypass
• residential gateways, hosted, access and enterprise applications;
• digital media gateways with various capacities for wireless, wireline, cable, enterprise, fixed mobile convergence, and unified communications;
• multi-service business gateways for integrated voice, data and security access for service providers connecting enterprise customers to their network and for the enterprise branch office;
• IP phones for enterprise and managed services service providers;
• mobile VoIP access solutions; media servers for enhanced voice and video services and functionalities, such as conferencing, video sharing and messaging (IPmedia Media Servers), and value-added applications for unified communications.

The Company’s Technology products on the other hand serves as building block for network level products. These would include the following:

• voice over packet processors;
• VoIP communication boards;
• media processing boards for enhanced services and functionalities
• voice and data logging hardware integration board products.

The Company competes with several other companies, to wit:

• Cisco Systems, Inc.,
• Mediatrix Telecom, Inc.,
• Vega Stream Limited,
• Samsung,
• Innovaphone AG,
• Net.com/Quintum Technologies,
• Tainet Communication System Corp.,
• Welltech,
• Ascii Corp.,
• D-Link Systems, Inc.,
• Multitech Inc.,
• Inomedia,
• Grandstream,
• OKI, LG.,
• Pirelli Broadband (ADB),
• Technicolor,
• Sagemcom,
• Zyxel,
• Netgear,
• Bewan (Pace),
• Amper,
• Huawei,
• FiberHome,
• ZTE,
• Adtran,
• Oneaccess,
• ACME Packets (Covergence),
• SIPera,
• Ingate,
• Edwater,
• Alcatel-Lucent,
• Nokia-Siemens,
• Ericsson,
• UTstarcom,
• ZTE
• Cisco,
• Dialogic,
• Sonus Networks,
• General Bandwidth,
• Commatch (Telrad),
• Veraz Networks,
• Hewlett-Packard,
• Comverse-NetCentrex,
• Nortel,
• Texas Instruments,
• Broadcom,
• Infineon,
• Centillium,
• Surf and Mindspeed.,
• Dialgic/NMS Communications/Cantata
• and PIKA Technologies, Inc.

AudioCodes Ltd. (NASDAQ: AUDC) 52 week: 2.28 – 6.39   Mkt cap: 98.07M   Shares: 41.20M

Incorporated in 1995, Athersys, Inc. Incorporated is a biopharmaceutical company which is engaged in the discovery and development of therapeutic product candidates. The Company has established a pipeline of therapeutic product development programs in multiple disease areas. The company’s product development portfolio includes MultiStem, a stem cell product that it had developed as a treatment for multiple disease indications, and is being evaluated in clinical trials. Treatment for obesity and related metabolic conditions are likewise developed by the Company by focusing on the development of compounds which would act through the stimulation of a specific receptor in the brain that controls appetite. It also focuses on the development of  small molecule compounds for the treatment of certain neurological conditions, and for the modulation of stem cells or related applications in the regenerative medicine area. In 2010, the Company together with RTI Biologics Inc. entered into an agreement for the development and commercialization of multiptent adult progenitor cell technology-based biologic implants which are used for orthopedic applications.

Through MultiStem, The Company has established therapeutic product development programs for the treatment of certain areas including:

• cardiovascular disease,
• neurological disease
• immune system disorders.

In the year 2010, several programs had been created by the company under the clinical development stage. These programs include the following

• Phase II clinical study which involves the administration of MultiStem to patients suffering from Ulcerative colitis, which study is authorized by the US Food and Drug Administation
• Phase I clinical study involving administration of MultiStem to patients suffering from an acute myocardial infarction (AMI), more commonly referred to as a heart attack
• Phase I clinical study involving administration of MultiStem to patients suffering from leukemia or certain other blood-borne cancers.

Athersys, Inc. (NASDAQ: ATHX) 52 week: 1.00 – 3.02   Mkt cap: 40.57M   Shares:  29.40M

Incorporated in 1985, Asure Software Inc. (the Company) provides Web-based workforce management solutions which would enable organizations to manage their office environment and human resource and payroll processes. The workforce management solutions include the following services:

• scheduling software,
• human resource and time and attendance software,
• complementary hardware devices to its software products,
• software maintenance and support,
• installation and training
• other professional services.

The two product lines in which the company offers its workforce management solutions are NetSimplicity and iEmployee. The NetSimplicity line of software enables corporations, educational institutions, healthcare facilities and law firm both in the United States and across the globe a more manage shared office space, equipment, assets and resources. The Company provides for Meeting Room Manager which is marketed both on an in-house installed, perpetual license basis, and on a hosted subscription, software-as-a-service (SaaS) basis. This Meeting Room Manager has evolved into a scheduling solution which would enable organizations to better manage their meeting environment through the management of meeting room environment namely:

• rooms,
• catering, audio/video (A/V),
• equipment,
• setup and other resources and services.

In addition thereto, the Company also offers complementary LCD panels as an option as a means to gain access to its scheduling software and book rooms adhoc through panel interfaces.

On the other hand, the Company’s iEmployee suite of time and attendance and human resources software enables small to medium-sized businesses to transition to an online, self-service human resources process. These iEmployee products are offered on a hosted subscription, SaaS basis thereby saves customers the need to install software or maintain hardware and provides customers a quick and easy way to implement a fully-automated human resource information system solution. All the more, these products are integrated with payroll and benefits providers which would allow customers to advance to online, self-service human resource without switching costs.

The Company’s two primary iEmployee products are Time & Attendance and HR & Benefits. This one unified system would enable organizations to eliminate paper timekeeping hassles through the management of hourly time tracking, project time tracking and paid of time. In 2010, iEmployee TTG-400 Time clock was introduced by the Company which would allow employers to capture employee time punches with the use of wide range of biometric and card recognition options.

Asure Software Inc. (NASDAQ: ASUR) 52 week: 2.25 – 8.95   Mkt cap: 21.72M   Shares:  3.09M

A holding company incorporated in 1996, Asia Pacific Wire and Cable Corporation Limited (the Company) is engaged in the manufacture and distribution of telecommunications (copper and fiber optic) and power cable, and enameled wire products. These products are distributed all over the Asia Pacific Region more particularly in Singapore, China, Thailand and Australia. The Company not only produces its own wire and cable products but it also distributes and sells products made by Pacific Wire and Cable Company. The Company is likewise providing project engineering services for the supply, installation and delivery of power cables to its customers.

The principal business line of the Company consists of the following:

• manufacture of wire and cable products,
• distribution of its own manufactured products and of certain wire and cable products manufactured by PEWC,
• provision of project engineering services to certain of its customers.

A variety of wire and cable products are sold by the Company which are used in a wide range of infrastructure projects as well as in commercial and residential developments. The enameled wire products are used in the manufacture of components and sub-components of appliances and small machineries. On the other hand, electronic cables which comes in the form of cable harnesses are utilized in the following:

• electronics
• computer
• building automation
• audio and communication industries.

The Company also produces a variety of bundled telecommunications cable which is used for telephone and data transmissions that may be used in various internal and external environments. These cables produced include copper-based and fiber optic cables. A range of armored and unarmored low voltage power transmission cable is also produced by the Company which is practically used to transmit electricity to and within commercial or residential buildings as well as street lights and other traffic signals. Lastly, the Company manufactures a wide array of enameled wires with sizes which are used in certain types of petroleum insulation materials like polyvinyl formal, polyurethane wire and polyester.

Asia Pacific Wire & Cable (NASDAQ: APWC) 52 week: 1.92 – 6.85   Mkt cap: 45.78M   Shares: 13.83M

Arrythmia Research Technology Inc. (the Company) is engaged in the development of medical software that analyzes electrical impulses of the heart which will detect and aid in the treatment of potentially lethal arrhythmias. In 2010, the Company purchased RMDDx Corporation, through its subsidiary, RMDDxUSA Corp. The Company’s products consist of signal-averaging electrocardiographic (SAECG) software which is named PREDICTOR series. This SEAG product is utilized primarily in a National Institutes for Health funded investigation into Risk Stratification in MADIT II Type patients.  The Company’s wholly owned subsidiary named Micron Products Inc. manufactures and distributes the following:

• Silver and non-silver plated conductive resin sensors
• Metal snap fasteners
• Assembly machines to its sensor and snap customers

The silver and non-silver plated conductive resin sensors which are used in the manufacture of disposable integrated electrodes constituting a part of electrocardiographic diagnostic and monitoring instruments. Micron likewise is a distributor of metal snap fasteners which are also utilized in the manufacture of disposable electrodes. And in addition thereto, the Micron also sells assembly machines to its sensor and snap customers.

The Silver/silver-chloride sensors are provided by Micron to the medical device industry. The customers manufacture monitoring and transmitting electrodes, which are then used in a wide range of bio-feedback and bio-stimulation applications which include among others:

• electrocardiograms (ECG’s),
• electroencephalograms (EEG’s),
• electro-muscular stimulation (EMS),
• thermo-electrical neural stimulation (TENS).
• precision plastic products.

On the other hand, Micron Integrated Technologies (MIT) which is a division of Micron is engaged in the production of metal and plastic components and assemblies for the medical and defense industries.

The silver-plated and the non-silver plated conductive resin sensors produced and distributed by Micron is utilized for manufacturing disposable electrodes used in ECG diagnostic, monitoring and related instrumentation. They are widely utilized in coronary care units, telemetry units, and for other monitoring purposes.  These sensors consist of molded plastic substrate plated with silver or silver chloride surface, a sensitive conductor of electrical signals.

The Company’s Metal snap fasteners on the other hand are used as attachment and conductive connection for disposable electrode and lead wires of ECG machines. These snap fasteners are purchased by Micron for resale to suppliers.

Arrhythmia Research Technology, Inc. (NYSEAMEX: HRT) 52 week: 2.80 – 6.10   Mkt cap: 8.57M   Shares:  2.79M

Array BioPharma Inc. (the Company) is a biopharmaceutical company that is engaged on the discovery, development and commercialization of small molecule drugs for the treatment of patients afflicted with inflammatory diseases and cancer. The Company’s drug development pipeline includes among others clinical candidates designed to regulate therapeutically significant target pathways. The following are the Company’s drug candidates:

• AMG 151
• MEK 162
• ARRY-380
• ARRY-520
• ARRY-543
• ARRY-614

In 2009, Amgen was granted by the company global rights to the small molecule glucokinase activator program which includes the AMG 151. These activators represents a new class of drugs which are used for the treatment of Type 2 diabetes. Gluconikase on the other hand is a type of enzyme which senses glucose in the pancreas.  In 2010, Novartis through a License Agreement was granted by the Company a right to develop and commercialize the following:

• MEK 162, which is in a Phase I cancer trial
• ARRY-300
• Other specified MEK inhibitors

HER2 which is also known as ErbB2 is a receptor of tyrosine kinase. It is over-expressed in breast, gastric and ovarian cancer. What modulates HER2 is Herceptin (trastuzumab), an intravenously-dosed protein inhibitor. It was approved for HER2 positive metastatic breast cancer patients as well as adjuvant survery in early breast cancer patients.

ARRY 520 has showcased its efficacy in preclinical hematological tumor models with respond rates observed in myeloid leukemia and multiple myeloma models. It inhibits kinesin spindle protein which plays a vital role in mitotic spindle formation.

HER2 and EGFR on the other hand are receptor kinase which target over-expressed malignancies, including breast, lung, pancreas, colon, head and neck cancers.

P38 regulates the production of numerous cytokines including TNF, IL-1 and IL-6 the increased production of which will lead to inflammation and aberrant tissue proliferation. An orally active compound, ARRY 614 inhibits both p38 and Tie2. It is likewise found in preclinical models which will block angiogenesis, inhibit inflammation and antagonize tumor growth having little side effect profile after prolonged dosage.

Array BioPharma Inc. (NASDAQ: ARRY) 52 week: 1.58 – 3.80   Mkt cap: 222.82M   Shares: 61.55M

A defense and security products and services company, Arotech Corporation  (the Company) is engaged in three business areas namely:

• interactive simulation for military, law enforcement and commercial markets;
• batteries and charging systems for the military,
• high-level armoring for military and nonmilitary air and ground vehicles.

The company operates through its wholly owned subsidiaries which are the divided into three, namely:

• training and simulation division
• Armor division
• Battery power Systems Division

On 2010, the Company’s Vehicle Simulations group accounted for 54% of its Training and Simulation Division’s revenues; the Military Operations Group accounted for 24% while its Use of Force group accounted for 22%.

Training and Simulation Division

The Company is developing, manufacturing and marketing advanced high-tech multimedia and interactive digital solutions. Through its Training and Simulation Division, these solutions are utilized for for use-of-force training and driver training of military, law enforcement, security and other personnel. The Company is providing simulators, systems enginieering and software products to the United States Military. Through its subsidiary, FAAC Incorporated which is located in Michigan, it provides specialiazed use of force training to the police, security personnel and the military under the trade name IES Interactive Training.

Battery and Power Systems Division

Through its Battery and Power systems Division, lithium and Zinc-Air batteries for defense and security products are manufactured and sold by the Company successfully. These rechargeable and primary lithium batteries and smart chargers are developed and sold to both the military and private defense industries in the following regions:

• Middle East
• Europe
• Asia (through through its subsidiary Epsilor Electronic Industries, Ltd., located in Israel)

Armor Division

Through its Armor Division, it manufactures military armored combat vehicles which are based on commercial platforms, up-armor commercial vehicles which are used for civilian SUVs, vans and buses.  and armor kits for aircraft and vessels. They utilized lightweight ballistic materials, special ballistic glass and advanced engineering processes. Lastly through the company’s MDT Armor, it provides ballistic armor kits for rotary and fixed wing aircraft under the trade name Armour of America.

Arotech Corporation (NASDAQ: ARTX) 52 week: 1.11 – 2.47   Mkt cap: 20.00M   Shares:  15.62M

Arena Pharmaceuticals Inc. (the Company) is a clinical-stage biopharmaceutical company. Incorporated on 1997, it is geared towards the discovery, development and commercialization of oral drugs that target G protein-coupled receptors (GPCRs) in four major therapeutic areas namely:

• cardiovascular,
• central nervous system,
• inflammatory
• metabolic diseases.

The Company’s advance drug candidate is lorcaserin hydrochloride (lorcaserin) which is utilized for weight management. It has completed two pivotal phase III clinical trials.

Arena Pharmaceuticals GmbH (Arena GmbH), The Company’s wholly owned subsidiary, has granted Eisai Inc. (Eisai) the rights to commercialize lorcaserin in the United States and its territories and possessions subject to Food and Drug Administration (FDA) approval. The company’s research and development programs also include the following:

• APD597, APD916, APD791 and APD125, all of which are oral drug candidates.
• APD597, which targets the GPR119 receptor, is intended for the treatment of type 2 diabetes, and has completed a Phase I clinical trial program under the Company’s former collaboration with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Ortho-McNeil-Janssen).
• APD916 is histamine H3 inverse agonist intended for the treatment of narcolepsy with cataplexy, and has completed a Phase I clinical trial.
• APD791 is an inverse agonist of the serotonin IIA receptor intended for the treatment of arterial thrombosis and other related conditions, and has completed Phase Ia and Phase Ib clinical trials.
• APD125 is a serotonin IIA receptor inverse agonist that it studied for insomnia, and has completed Phase IIa and Phase IIb clinical trials.

In 2010, the third Phase III clinical trial for lorcaserin the BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) trial has been reported by the Company. The BLOOM and BLOSSOM trials which evaluated 7,190 patients for two years were included in the initial Phase III clinical trials for the NDA for lorcaserin.  Likewise, the Company evaluated the safety and efficacy of lorcaserin for the for weight management in 604 obese and overweight patients with type 2 diabetes in its Phase III BLOOM-DM trial. Also in 2010, the Company has initiated a Phase I clinical trial to evaluate the single ascending doses of APD881, an orally viable agonist of the protascyclin receptor which is intended for the treatment of pulmonary arterial hypertension. Pulmonary Arterial Hypertension is a progressive, life threatening disorder which is characterized by increased pressure in the arteries which carry blood from the heart to the lungs.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) 52 week: 1.23 – 3.47   Mkt cap: 472.71M   Shares: 180.42M

Incorporated in 1967, Arabian American Development Company (the Company) is engaged in the manufacture of specialty petrochemical products. It acquired 100% of Silsbee Trading and Transportation Company in the year 2010 and currently, the Company’s activities in the United States are conducted through a wholly owned subsidiary, the Texas Oil and Chemical Co. II, Inc (TOCCO). TOCCO owns South Hampton Resources Inc, which in turn owns Gulf State Pipeline Company. The Company also directly owns approximately 55% interest in mining company, Pioche-Ely Valley Mines, Inc. (PEVM).

South Hampton operates a specialty petrochemical facility located near Silsbee Texas located approximately 30 miles north of Beaumont, Texas, and 90 miles east of Houston. It creates petrochemical solvents and other petroleum based products which includes iso-pentane, normal pentane, isohexane and hexane, which may be used in the production of the following:

• polyethylene,
• packaging,
• polypropylene,
• expandable polystyrene,
• poly-iso/urethane foams,
• catalyst support industry.

The facility of South Hampton consists of six operating units which, make distinct products through differing processes namely:

• a Penhex Unit which has the capacity to process approximately 6,700 barrels per day of fresh feed
• a Reformer, Cyclo-pentane Unit, Aromax Unit which further process the streams produced by the Penhex Unit
• an Aromatics Hydrogenation Unit which has a capacity of 400 barrels a day
• and a White Oil Fractionation Unit which has a capacity of 3,000 barrels per day.

To support the Penhex and Cyclo-pentane Units, the Reformer and Aromax units are put into operation. There are also two other operating units located at the plant site namely Aromatics Hydrogenation Unit and a White Oils Fractionation Unit. These are operated as two independent and completely segregated processes which are dedicated to the needs of two different toll processing customers.

Gulf State on the other hand owns and is operating three pipelines which connect the South Hampton facility to:

• a natural gas line
• to South Hampton’s truck and rail loading terminal
• major petroleum products pipeline owned by an unaffiliated third party.

Arabian American Development Company (NYSE: ARSD) 52 week: 3.16 – 10.95   Mkt cap: 230.94M   Shares: 23.74M